Loading
NHWD-870 is an experimental small molecule from Zhejiang Wenda Pharma, in phase 2 trials for NUT carcinoma and lung squamous cell carcinoma with NSD3 alterations.
NHWD-870 (zepubresib hydrochloride) is a small molecule (oral) from Zhejiang Wenda Pharma. A BET bromodomain inhibitor that separates BRD4 from the MYC enhancer and lowers MYC expression, which slows cancer cell growth. Its furthest stage is phase 2, for NUT carcinoma and lung squamous cell carcinoma with NSD3 alterations. ClinicalTrials.gov registers it in 2 studies linked below. Company pipeline says phase 2. Registry: phase 2 NCT06527300 in advanced NUT carcinoma (status UNKNOWN, i.e. not updated); compassionate-use study NCT06073938 sponsored by Hunan Province Tumor Hospital (status UNKNOWN). Whether it works in people has not been established unless a trial below reports it.
A BET bromodomain inhibitor that separates BRD4 from the MYC enhancer and lowers MYC expression, which slows cancer cell growth. Connects to BRD4.
1.NHWD-870 slips into a pocket on BRD4.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"NHWD-870" OR ABSTRACT:"NHWD-870" OR TITLE:"zepubresib hydrochloride" OR ABSTRACT:"zepubresib hydrochloride") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NHWD-870, not a curated reading list.
Shares Zhejiang Wenda Pharma and the tag pipeline.
Shares Zhejiang Wenda Pharma and the tag pipeline.
Shares BRD4 and the tag pipeline.
Shares Zhejiang Wenda Pharma, BRD4.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/